000 | 00899 a2200241 4500 | ||
---|---|---|---|
003 | OSt | ||
005 | 20240229113924.0 | ||
008 | 240221b |||||||| |||| 00| 0 eng d | ||
020 | _a9789351072720 | ||
040 | _cCUS | ||
082 |
_a615.19 _bSIL/O |
||
100 |
_aSilverman, Richard B _925768 |
||
245 | _aThe Organic Chemistry of Drug Design and Drug Action | ||
260 |
_aLondon: _bElsevier, _c2022. |
||
300 | _a517p. | ||
505 | _aIntroduction Lead discovery and lead modification Receptors Enzymes Enzyme inhibition and inactivation Dna-interactive agents Drug resistance and drug synergism Drug metabolism Prodrugs and drug delivery systems | ||
650 |
_aOrganic chemistry of drug design and drug action _925769 |
||
650 |
_adrug synergism _925770 |
||
650 |
_aEnzymes _918671 |
||
650 |
_aEnzyme inhibition _925771 |
||
700 |
_aHolladay, Mark W. _925772 |
||
942 |
_2ddc _cWB16 |
||
999 |
_c214046 _d214046 |